NHLBI Emerging Investigator Award (EIA) (R35 Clinical Trial Optional)
The NHLBI Emerging Investigator Award (EIA) provides long-term support for experienced PDs/PIs with a strong research record to make significant contributions to heart, lung, blood, and sleep research.
Funder: National Institutes of Health
Due Dates: February 19, 2025 (New) | April 28, 2025 (AIDS) | February 19, 2026 (New) | April 28, 2026 (AIDS) | February 19, 2027 (New) | April 28, 2027 (AIDS)
Funding Amounts: Up to $700,000 direct costs per year for up to 7 years; up to 20 new awards per year; total program funding up to $20M/year (across this and companion NOFOs).
Summary: Long-term, flexible support for experienced investigators to advance innovative heart, lung, blood, and sleep research programs.
Key Information: Applicants must currently hold at least two NHLBI R01-equivalent awards (one as an NHLBI-funded ESI R01); EIA replaces most NHLBI individual research grants.
Description
The NHLBI Emerging Investigator Award (EIA) provides experienced Program Directors/Principal Investigators (PDs/PIs) with stable, long-term funding to support a research program—rather than a single project—within the mission of the National Heart, Lung, and Blood Institute (NHLBI). The EIA is designed to foster scientific productivity and innovation by offering up to seven years of support, increased flexibility to pursue new research directions, and reduced administrative burden. The award is intended to be the primary, and in most cases sole, source of NHLBI funding for individual research grants during the project period.
The EIA supports research programs that make major contributions to heart, lung, blood, and sleep (HLBS) research. It allows investigators to take greater risks, pursue ambitious or long-term projects, and devote more time to research and mentoring.
